Consistent with previous studies (24, 29), we observed elevated serum Galectin-9 levels in patients with T2DM (Supplementary Figure S6E), suggesting the soluble Galectin-9 may negatively regulate the immune response via Galectin-9/Tim-3 pathway. Here, LGALS9 is linked to type 2 diabetes mellitus.